{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"43.6","upperLimit":"57.8","value":"50.7"},{"groupId":"OG001","lowerLimit":"57.6","upperLimit":"81.1","value":"70.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"203"},{"groupId":"OG001","value":"64"}],"units":"Participants"}],"description":"MCyR is defined as percentage of participants with complete cytogenetic response (CCyR) or partial cytogenetic response (PCyR). Cytogenetic response is the percentage of Philadelphia chromosome positive (Ph+) metaphases in bone marrow (BM). Response is further defined as MCyR: CCyR or PCyR, where CCyR: no Ph+ cells; PCyR: 1 to 35% Ph+ cells.","dispersionType":"95% Confidence Interval","groups":[{"description":"CP-CML participants R-I to dasatinib or nilotinib were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).","id":"OG000","title":"Cohort A: CP-CML R-I"},{"description":"CP-CML participants who had T315I mutation of breakpoint cluster region-Abelson complex (BCR-ABL) were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).","id":"OG001","title":"Cohort B: CP-CML With T315I Mutation"}],"paramType":"NUMBER","populationDescription":"Treated population included all participants assigned to Cohorts A to F who received at least 1 dose of ponatinib. The data for this outcome measure is applicable for Cohorts A and B only.","reportingStatus":"POSTED","timeFrame":"Up to 12 months after initiation of study treatment","title":"Percentage of CP-CML Participants With Major Cytogenetic Response (MCyR)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}